The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin.
M. A. Blazer
Consultant or Advisory Role - Eisai
J. Reardon
No relevant relationships to disclose
D. Efries
No relevant relationships to disclose
Y. T. Smith
No relevant relationships to disclose
L. M. Weatherby
No relevant relationships to disclose
K. Juergens
No relevant relationships to disclose
T. Criswell
No relevant relationships to disclose
J. S. Rose
No relevant relationships to disclose
G. S. Phillips
No relevant relationships to disclose
N. Griffith
Consultant or Advisory Role - Eisai
T. S. Bekaii-Saab
No relevant relationships to disclose